TYRA

TYRA BIOSCIENCES, INC.

TYRA · CIK 1863127 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20212025
Net Income−$120M
20212025
Operating CF−$95M
20212025
Free Cash Flow−$95M
20212025

Income Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.1B$0.1B$0.1B$0.0B$0.0B
SG&A Expense
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-2.01$-1.51$-1.62$-1.32
EPS (Diluted)$-2.01$-1.51$-1.62$-1.32

Balance Sheet

MetricFY 2025FY 2024FY 2023FY 2022FY 2021
Total Assets$0.3B$0.4B$0.2B$0.3B$0.3B
Current Assets$0.3B$0.3B$0.2B$0.3B$0.3B
Cash & Equivalents$0.1B$0.1B$0.1B$0.3B$0.3B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.3B$0.2B$0.3B$0.3B

Cash Flow Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$0.1B$-0.1B$-0.1B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.2B$0.0B$0.0B$0.3B